No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression. by Furukawa, Toshi A et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/ACPS.13145
 This article is protected by copyright. All rights reserved
PROFESSOR TOSHI A. FURUKAWA (Orcid ID : 0000-0003-2159-3776)




No benefit from flexible titration above minimum licensed dose in 
prescribing antidepressants for major depression
Toshi A. Furukawa, MD, PhD*†
Departments of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto 
University Graduate School of Medicine / School of Public Health, Kyoto, Japan
furukawa@kuhp.kyoto-u.ac.jp
Georgia Salanti, PhD*
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
georgia.salanti@ispm.unibe.ch
Philip J. Cowen, MD, FRCPsych










This article is protected by copyright. All rights reserved
Stefan Leucht, MD
Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of 
Munich, Munich, Germany
stefan.leucht@tum.de
Andrea Cipriani, MD, PhD
Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK 
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
andrea.cipriani@psych.ox.ac.uk
* equal contribution
†Corresponding author: Department of Health Promotion and Human Behavior, Kyoto 
University Graduate School of Medicine / School of Public Health, Yoshida Konoe-cho, Sakyo-










This article is protected by copyright. All rights reserved
ABSTRACT
Background: In fixed dose antidepressant trials, the lower range of the licensed dose achieves 
the optimal balance between efficacy and tolerability. Whether flexible upward titration 
while side effects permit provides additional benefits is unknown.
Methods: We did a systematic review of placebo-controlled randomised trials that examined 
selective serotonin reuptake inhibitors (SSRIs), venlafaxine or mirtazapine in the acute 
treatment of major depression. Our primary outcome was response, defined as 50% or 
greater reduction in depression severity. Secondary outcomes included dropouts due to 
adverse effects and dropouts for any reason. We conducted random effects meta-analyses to 
calculate the ratios of odds ratios (RORs) between trials comparing the flexible dose titrating 
above the minimum licensed dose against placebo and those comparing the fixed minimum 
licensed dose against placebo.
Results: We included 123 published and unpublished randomized controlled trials (29,420 
participants). There was no evidence supporting efficacy of the flexible dosing over the fixed 
low dose of SSRIs (ROR 0.96, 95%CI: 0.73 to 1.25), venlafaxine (1.24, 0.96 to 1.60) or 
mirtazapine (0.77, 0.33 to 1.78). No important differences were noted for tolerability or for 
any subgroup analyses except the superior efficacy of venlafaxine flexible dosing between 75-
150 mg over the fixed 75 mg (1.30, 1.02 to 1.65).
Conclusion: There was no evidence to support added value in terms of efficacy, tolerability or 
acceptability of flexibly titrating up the dosage over the minimum licensed dose of SSRIs or 
mirtazapine. For venlafaxine, increased efficacy can be expected by flexibly titrating up to 
150 mg.
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Summations:
 In the acute phase treatment of major depression, flexibly titrating the dose while side 
effects permit above the minimum licensed dose in SSRIs or mirtazapine provides no 
increase in efficacy and acceptability and no decrease in tolerability over fixed 
prescribing at the minimum dose.
 For venlafaxine, flexible titration up to 150 mg/day but not beyond was more efficacious 
than fixed dose at 75 mg/day.
Considerations:
 The comparison between the flexible dosing and the fixed dosing was across studies and 
not randomized within studies and therefore may be subject to confounding.
 For some comparisons, there were limited numbers of studies and the confidence 
intervals of the pooled estimates were wide.
 Because the findings are based on aggregate data meta-analysis, the conclusions apply to 
the group average: for individual patients the dosage needs be adjusted around the 
optimum group average, taking into account such individual characteristics as age, body 
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INTRODUCTION
Antidepressant pharmacotherapy is currently the most widely used treatment for depression. 
Second-generation antidepressants, particularly selective serotonin reuptake inhibitors 
(SSRIs), are recommended as first-line options in the pharmacological management of major 
depression (1).
Every antidepressant has a range of licensed dosages. For example, in the case of fluoxetine, 
the most classical SSRI, the dose range approved by the US Food and Drug Administration is 
between 20 to 80 mg/day.  International guidelines recommend conflicting strategies as to 
where in this wide range the clinicians should target the dosage (1, 2). Our recent dose-
response meta-analysis of SSRIs has shown that both response and remission gradually 
increase up to doses between 20 and 40 mg fluoxetine equivalents, with no further increase 
or even a slight decrease at higher doses. Dropouts due to adverse effects showed a steep 
increase through the examined range. Consequently, the lower range of the licensed doses 
(between 20 and 40 mg fluoxetine equivalents) achieves the optimum balance between 
efficacy, tolerability and acceptability.  (3).
These findings were based on fixed dose randomized controlled trials (RCTs) (3). However, 
fixed-dose studies typically use rapid or no titration and this may exaggerate dropouts and 
underestimate efficacy (3-5). By contrast, the flexible dose regimen that titrates upward or 
downward in view of each patient’s response and side effects may decrease dropouts and 
increase response. Real-world practices are better represented by such flexible-dose studies 
and consequently the optimal target dose range in practice could be higher than those 
suggested by fixed regimen studies (4). However, there has been to date no empirical data to 
support this claim.
This study aims to examine whether flexible increasing above the minimum licensed dose is 
more beneficial than prescribing the fixed minimum licensed dose. The two approaches are 
compared in terms of efficacy, tolerability and acceptability. As only few studies have directly 
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METHODS
Study search and selection
This study uses the trials identified in a previously published systematic review with 
network meta-analysis (6, 7).  We have searched the Cochrane Central Register of Controlled 
Trials, CINAHL, Embase, LILACS, MEDLINE, MEDLINE In-Process, PsycINFO, AMED, 
the UK National Research Register, and PSYNDIX, as well as the website of the national 
drug licensing agencies in six countries (USA, UK, Netherlands, Sweden, Japan and 
Australia), the European Medicines Agency, and trial registries for published, unpublished 
and ongoing RCTs. We contacted relevant pharmaceutical companies and asked for 
supplemental unpublished information as well as the National Institute for Health and Care 
Excellence (UK), the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen 
(Germany) and relevant individuals for additional information. Search was conducted with 
broad search terms for depression (depress* or dysthym* or adjustment disorder* or mood 
disorder* or affective disorder* or affective symptom*) in combination with generic and 
commercial names of all antidepressants under consideration. We also scrutinised reference 
lists of all the identified documents. There was no language restriction. The search was last 
updated on January 8, 2016. The complete dataset is accessible on Mendeley 
(https://data.mendeley.com/datasets/83rthbp8ys/2). There was no indication of small study 
effect or reporting bias in this dataset (6).
We had originally included double-blind, randomised controlled trials (RCTs) comparing 
antidepressants among themselves or against placebo in the acute phase treatment of adults 
(aged 18 or older) of both sexes, with a primary diagnosis of major depressive disorder 
according to standard operationalised diagnostic criteria. Studies focusing on patients with 
depression with another psychiatric disorder or a serious concomitant physical illness as well 
as those on bipolar, chronic, or treatment-refractory depression were excluded.
The current study builds upon our previous dose-response meta-analyses (3) that focused on 
the most frequently prescribed new-generation antidepressants in the UK according to Open 
Prescribing (8), namely five SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, 
sertraline), venlafaxine and mirtazapine. In this study we included all RCTs that 
administered these drugs either on a fixed dose regimen at their respective minimum 
licensed dose or a flexible dose regimen that allowed titration above the minimum dose, side 
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escitalopram, 20 mg for fluoxetine, 20 mg for paroxetine (paroxetine CR was calculated into 
paroxetine dosage by multiplying by 0.8 (9)), 50 mg for sertraline, 75 mg for venlafaxine and 
15 mg for mirtazapine. The fixed dose studies in the current analyses were therefore those 
which compared these dosages against placebo. The flexible dose studies were then defined 
as those which compared drug arms which allowed upward titration beyond these minimum 
dosages against placebo.
Outcomes
Our primary outcome was response, defined as 50% or greater reduction from baseline on an 
observer-rated depression severity scale. Secondary outcomes included depression severity 
measured on a continuous scale, dropouts due to adverse effects as an index of treatment 
tolerability, and dropouts for any reason as an index of overall treatment acceptability. We 
recorded the outcomes as close to 8 weeks as possible for all analyses (range: 4-12 weeks).
When depressive symptoms had been measured with multiple instruments, we followed a 
predefined hierarchy prioritizing the Hamilton Rating Scale for Depression (HAMD), then 
Montgomery-Åsberg Depression Rating scale, then any other validated observer-rated 
measure. In the absence of information or supplemental data from the authors, response 
rates were calculated according to a validated imputation method (10). When SDs were not 
reported, but SEs, t-statistics or p values were reported, they were transformed to SDs (11). 
When SDs were not available and were not provided by the authors upon request, the mean 
value of known SDs from the included studies were used (12). A sensitivity analysis in the 
original network meta-analysis confirmed the robustness of these imputations (6). We set the 
number of patients who were randomly assigned as the denominator for all outcomes, 
assuming that patients lost to follow-up had dropped out without experiencing response or 
dropout due to adverse effects (13). When there were discrepancies in the reported data 
across multiple sources, we gave priority to unpublished information (7). Study selection and 
data extraction were conducted by at least two independent raters; any discrepancy was 
resolved by consensus of the study team. More detail about data extraction of outcomes can 
be found in the previous publications (3, 6, 7).
We set the dichotomous measure of response, rather than the continuous measure of 
depression severity, as our primary outcome in concert with the original network meta-
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because the former enables analyses as per the intention-to-treat principle by assuming 
dropouts from assessment to be non-responders (14, 15).
Data analyses
Our primary comparison of interest was between the fixed dose regimen at the lowest of each 
drug’s licensed dose range and the flexible dose regimen which allows upward titration going 
above that lowest dose while side effects permitted. 
We first calculated summary odds ratios of each drug over placebo among the fixed dose 
regimen studies (ORFixed) and those of the flexible dose regimen studies (ORFlex). We then 
calculated the ratio of the two ORs (ROR= ORFlex / ORFixed) for the same drug. The ROR can 
be interpreted as the indirect OR between the flexible and fixed dosing of the same drug, 
with an ROR>1 indicating superiority of the flexible regimen over the fixed one. The five 
drug-specific RORs for the SSRIs were then further meta-analysed to obtain a summary 
ROR for the SSRIs; RORs for venlafaxine and mirtazapine were reported separately. In the 
case of multi-arm studies which contributed to two or more of the above comparisons (e.g. a 
study comparing fixed doses of two different drugs versus placebo, or a study comparing fixed 
and flexible doses of the same drug versus placebo), we divided the number of participants in 
the placebo arm appropriately to avoid double-counting them in the summary ORs or RORs 
(11). The random effects model was used for all the meta-analyses and heterogeneity was 
measured using I2 and the heterogeneity variance. 
We applied the same analytical strategies to the dichotomous secondary outcomes. For the 
continuous secondary outcome of depression severity, we calculated the standardised mean 
difference (SMD) and the difference in SMDs (DSMD= SMDFlex – SMDFixed), with an SMD<0 
indicating greater reduction in severity of the flexible regimen over the fixed one.
Sensitivity analyses
Upward titration beyond 40 mg fluoxetine equivalents could be disadvantageous against the 
flexible regimen, because our previous analyses suggested a dose-response curve of SSRIs 
and mirtazapine that is possibly decreasing above 40 mg fluoxetine equivalents (3). In this 
dose-response meta-analysis of SSRIs, the following doses were considered equivalent to 
fluoxetine 20 mg: citalopram 20 mg, escitalopram 9 mg, paroxetine 17 mg, and sertraline 49 
mg. We therefore ran a sensitivity analysis limiting the flexible regimens to those that 
allowed titration only up to double the minimum licenced dosage (corresponding roughly 
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We also ran an additional sensitivity analysis in which we compared the flexible dose studies 
that allowed dose ranges below the minimum licensed dose against the fixed minimum 
licensed dose studies.
As the comparison of the effects of interventions between fixed and flexible dosing are not 
randomised i.e. participants were randomised within studies but not across studies, 
confounding is possible. We therefore examined the comparability of studies in study year, 
number of participants per study, average age of participants, proportion of women enrolled, 
baseline depression severity, or length of trial. If differences in variables were noted, we 
calculated adjusted ORs via meta-regression and re-calculated the RORs.
We conducted all analyses in R (version 3.6.1) using the meta package (version 4.9-6). The 




Characteristics of the included studies
We have included 123 RCTs (29,420 participants), which contributed 66 comparisons 
between minimum dose fixed regimens and placebo and 76 comparisons between flexible 
dose regimens and placebo (eFigure 1 in Appendix 1). We had obtained unpublished 
information for 78 of the 122 RCTs (63.9 %). Table 1 shows the demographic, clinical and 
other characteristics of the included studies by regimen and drug. The participants were 
typically in their 40s, predominantly women and scored slightly above 20 on the 17-item 
HAMD at baseline on average. The trials lasted around 8 weeks.
Primary outcome: response of SSRIs, venlafaxine and mirtazapine
Figure 1 shows the RORs of response in the flexible dose studies over the fixed dose studies 
for three subgroups of SSRIs, venlafaxine and mirtazapine. Moderate heterogeneity was 
observed in the meta-analysis of RORs of SSRIs (I-squared=59.3%, 95% confidence interval 
(CI): 0% to 84.8%, heterogeneity variance  τ2= 0.024). There were no important differences 
between the flexible and fixed dosing for SSRIs (ROR 0.96, 95%CI: 0.73 to 1.25). Similarly, 
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were uncertain with wide confidence intervals. Appendix 4 shows the individual study ORs 
for response, synthesized by drug and regimen (eFigures 2-5).
Secondary outcomes: depression severity, dropouts due to side effects, dropouts for any reason
Figure 2a shows the DSMD of depression severity; 2b RORs of dropouts due to side effects; 2c 
RORs of dropouts for any reason, respectively. There were no important differences between 
the flexible and the fixed regimens in any of the comparisons. Evidence for venlafaxine and, 
in particular, mirtazapine was imprecise. Flexible dosing of SSRIs might even be associated 
with more dropouts due to adverse events compared to fixed dosing (Figure 2b). 
Sensitivity analyses
Figure 3 compares flexible regimens that titrate only up to 40 mg fluoxetine equivalents 
versus fixed dose. The point estimates of RORs were broadly similar to those in Figure 1; 
however, the ROR for venlafaxine was 1.30 (1.02 to 1.65), in favour of the flexible dosing 
between 75-150 mg of venlafaxine over the fixed dosing staying at 75 mg.
Flexible dose studies starting below the minimum licensed dose were available only for 
citalopram, paroxetine and mirtazapine. The confidence intervals were wide and there was 
no evidence that flexible dosing allowing doses lower than the minimum licensed dose was 
any more or less efficacious than the fixed minimum licensed dose (Appendix 5, eFigure 5).
Examination of Table 1 suggested that fixed dose studies tended to be more recent and larger 
than flexible dose studies for all drugs. In a logistic regression model, the study year was 
significantly associated with the dosing regimen when the drug was controlled for (p=0.01) 
but not the average sample size per study (p=0.07). Appendix 5, eFigure 6 shows the results 
for SSRIs scaling the RORs to year 2000 via meta-regression on the study year. The ROR 
was essentially unchanged at 0.97 (0.77 to 1.24) but heterogeneity was reduced (the 
heterogeneity variance was reduced by 32%).
DISCUSSION
The study aimed to examine whether the flexible upward titration of antidepressants beyond 
their minimum licensed dose conferred any benefit above the fixed dosing at the minimum 
dose in the acute phase treatment of major depression. RORs of response between the 
flexible dose regimen going above the minimum licensed dose and the fixed dose regimen 









This article is protected by copyright. All rights reserved
venlafaxine or mirtazapine. The lack of evidence for difference in efficacy was confirmed 
when the regimens were compared in terms of depression severity. We could not detect any 
important differences in terms of tolerability and acceptability between the two regimens 
either. However, imprecision in the summary effects was considerable in some of these 
outcomes. 
In the literature the advantage of flexible or fixed dose regimens had been discussed from the 
viewpoint of clinical trial design. An earlier report found that flexible dose studies were more 
often able to detect statistically significant drug-placebo differences than fixed dose studies 
(16). More recent reports, however, have not found such a difference between the two types of 
clinical studies (17, 18). Our results are in line with these more recent reports.
We are aware of only one RCT that compared flexible dosing up to the minimum of licensed 
dosage versus flexible dosing up to double that dosage. It was a large-scale pragmatic trial 
comparing the initial strategy of titrating up to 50 mg versus 100 mg of sertraline if side 
effects permitted. Altogether 970 participants were allocated to the 50 mg/day and 1,041 to 
the 100 mg/day arms, but there was no statistically significant difference in terms of 
depression severity or burden of side effects between the two groups after nine weeks of 
treatment (19).
Our previous dose-response meta-analyses of the fixed dose studies suggested no increase in 
response going beyond 40 mg of fluoxetine equivalents for SSRIs or mirtazapine and limited 
increase in response for venlafaxine, but steeply increased dropouts due to side effects for all 
the agents (3). When we compare the current findings including flexible dose studies with 
these results based on fixed dose studies, flexible dosing was able to mitigate but not 
decrease the harms of the higher doses and was unable to boost efficacy. The higher efficacy 
beyond 75 mg for venlafaxine may be considered to be in line with our previous meta-
analysis, which suggested initially increasing efficacy up to around 75-150 mg, followed by a 
more modest increase thereafter.
In our previous report we suggested that these findings were consistent with the observation 
from PET studies that substantial (80%) blockade of the serotonin transporter occurs with 
minimum therapeutic doses of SSRIs and only small increases in occupancy become apparent 
with further dose escalation (20). A similar finding obtains with venlafaxine but the ability of 
venlafaxine to inhibit noradrenaline reupake at higher doses may account for its improved 
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Our results of no additional benefits from initial flexible dosing strategy going beyond the 
low dosage are also in line with those from dose escalation strategies as the second line 
treatment after initial treatment failure. RCTs and their meta-analysis have repeatedly 
found that non-response to the initial minimum dose does not justify dose escalation beyond 
the initial dose: for example, among non-responders to initial 20 mg of fluoxetine equivalents, 
increasing the dosage to 40 mg or 60 mg was not more efficacious than, and only as tolerated 
as, staying at 20 mg (22-25). A particularly well-designed study provides a neurobiological 
explanation that is consonant with the observations cited above: in this study patients with 
major depression who had not responded to 20 mg of paroxetine were randomized to further 
paroxetine increase to 30-50 mg or to addition of placebo: after six weeks, dose escalation 
neither increased serotonin transporter occupancy nor decreased depressive severity in 
comparison with continuing 20 mg of paroxetine (26).
The current analyses are not without some weaknesses. First, RORs are essentially indirect 
comparisons between the flexible dose regimen arms versus the fixed dose regimen arms via 
placebo arms. The estimates can then be confounded when effect modifiers are unevenly 
distributed between the comparisons involving the flexible dose arms and those involving the 
fixed dose arms. The fixed dose studies tended to be more recent  and larger than flexible 
dose studies. This finding is consistent with our previous observation that recent trials of 
antidepressants are employing the fixed dose regimen more frequently (27). Moreover, the 
study year has been suggested to be a surrogate marker for study quality and other secular 
changes in the trial characteristics (28). Adjusting for the study year reduced heterogeneity, 
as expected, but findings were in line with the overall results. Second, the current study is 
based on study-level summary statistics and we were unable to identify subgroups of 
patients who would potentially need upward or downward titration. We would need 
individual patient data to elucidate such subgroup differences. Clinically, however, this may 
be less of a problem because it is natural to adjust the dosages according to the individual 
patient’s characteristics such as body weight, past experiences with similar drugs, 
comorbidity including liver or renal functions, or age: the current study only recommends 
that the average of such upward or downward adjustments be around the minimum of the 
licensed range. Third, although we were able to include 122 studies representing 32,373 
participants, the confidence intervals around the pooled estimates were not always precise. 
The ROR of response for SSRIs was 0.96 (0.73 to 1.25), which would translate into a risk 
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difference in response to be the smallest worthwhile difference between two treatment 
regimens, the estimated confidence interval rules out the possibility of superiority of the 
flexible regimen over the fixed regimen. However, the confidence intervals were much wider 
for venlafaxine and mirtazapine. Fourth, most of the included studies were company-
sponsored phase II or III studies. As such, the focus of flexible titration may have been 
related more to tolerability or safety rather than efficacy. Also we do not have information 
about how fine-grained flexible dosing was in each study. There remains some possibility 
that flexible titration targeting at efficacy and conducted at smaller steps than was actually 
undertaken in the included studies might increase efficacy and/or tolerability. This remains 
an empirical question to be tested out. Lastly, the search date for this review could be 
considered old: however, an update search for eligible studies in PubMed in March 2019 
revealed no additional study.
The evidence about the dose-response relationship based on fixed dose studies (3), the 
evidence from dose escalation studies after non-response (22-25), the biological findings for 
transporter occupancy (20, 26), results from the megatrial directly comparing two doses (19), 
and our present comparison of the fixed versus flexible regimens, all converge to suggest that 
there is no added benefit going beyond the minimum dose for SSRIs and mirtazapine. 
Venlafaxine may be beneficially and harmlessly increased between 75-150 mg. Considering 
also the cost of increasing the dose, the present study suggests that we should no longer, 
speculatively without due evidence, advocate the policy of increasing the dosage above the 
minimum licensed dose of SSRIs and mirtazapine, until further evidence to the contrary 
becomes available.
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Figure 1. RORs of response of the flexible dose starting from the minimum licensed dose and 




Favours fixed low dose Favours flexible dose
ROR 95%CI
mirtazapine 0.77 [0.33; 1.78]
SSRI
Random effects model
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Figure 2. DSMDs of depression severity, RORs of dropouts due to side effects, RORs of 
dropouts for any reason
2a. DSMDs of depression severity of the flexible dose starting from the minimum licensed 
dose and titrating upward, over the fixed minimum licensed dose
Drug
-0.3 -0.2 -0.1 0 0.1 0.2 0.3
DSMD
Favours flexible dose Favours fixed low dose
SMD 95%-CI
mirtazapine -0.02 [-0.57; 0.52]
SSRI
Random effects model
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2b. RORs of dropouts due to side effects of the flexible dose starting from the minimum 




Favours flexible dose Favours fixed low dose
OR 95%-CI
mirtazapine 0.28 [0.06; 1.25]
SSRI
Random effects model


















venlafaxine 0.72 [0.39; 1.32]
2c. RORs of dropouts for any reason of the flexible dose starting from the minimum licensed 




Favours flexible dose Favours fixed low dose
OR 95%-CI
mirtazapine 0.70 [0.32; 1.54]
SSRI
Random effects model
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Figure 3. Sensitivity analysis: RORs of response of the flexible dose starting from the 
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Favours fixed low dose Favours flexible dose
OR
0.91
0.97
0.85
1.54
0.98
0.70
1.30
95%-CI
[0.69; 1.19]
[0.79; 1.19]
[0.68; 1.07]
[0.89; 2.67]
[0.78; 1.23]
[0.55; 0.89]
[1.02; 1.65]
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